Menu

Pharma News

16704526_l

Orion-CuraTeQ and Theramax-Enzene Biosciences partnerships

Home/Pharma News | Posted 18/02/2022

In January 2022, Finnish company Orion Corporation and CuraTeQ Biologics, subsidiary of India’s Aurobindo Pharma, announced their European expansion to the Baltic countries. This follows the December 2021 announcement that the UK’s Theramex entered into an agreement with India’s Enzene Biosciences to develop, register and commercialize a biosimilar of Roche’s RoActemra® (tocilizumab).

01 AA007239

Biocon–Viatris merger expected

Home/Pharma News | Posted 11/02/2022

The merger of India’s Biocon Biologics and Viatris’ biosimilar business are reported to be in advanced stages.  

Business Aquisition V13F07

Samsung to take full control of Samsung Bioepis

Home/Pharma News | Posted 04/02/2022

Korean electronics giant Samsung has made a deal with US biotechnology company Biogen Idec (Biogen) to take full ownership of their joint biosimilars venture, Korea-based Samsung Bioepis.

2021 V22A28

Top 10 most read GaBI Online articles in 2021

Home/Pharma News | Posted 28/01/2022

A review of the Top 10 most read articles reveals that biosimilars are still of most interest to readers. Some of the most memorable events for biosimilars in 2021 were recommendations for biosimilar approvals by the European Medicines Agency (EMA) and by China’s National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA), as well as summaries of biosimilar approvals in Uruguay and Paraguay. Other subjects of interest included naming for biosimilars in the US, the interchangeability of EU biosimilars, Federal purchases of biologicals for cancer in Brazil. Finally, how patent litigation creates barriers to US biosimilar market growth and how competition from biosimilars drives price reductions for biologicals in France was also of interest to readers.

Shaking hands V13D29

Fresh partnerships announced for ranibizumab and trastuzumab biosimilars

Home/Pharma News | Posted 21/01/2022

Prestige BioPharma has partnered with Dr Reddy’s Laboratories (Dr Reddy’s) to commercialize their trastuzumab biosimilar, HD201, while MS Pharma has joined up with Formycon for the commercialization of its ranibizumab biosimilar, FYB201.

24 AA011041

Spinoff updates: Merck’s Organon and Novartis’ Sandoz

Home/Pharma News | Posted 26/11/2021

Merck spinoff Organon has announced third quarter revenue of US$1.6 billion in 2021. This shows slight decline in women’s health medications but growth in biosimilar sales. Following its 2021 third quarter review, Novartis is considering the spinoff of its biosimilar division, Sandoz, as a standalone company.

28 MD002360

Swiss Social Democrat’s for nationalization of Sandoz

Home/Pharma News | Posted 19/11/2021

In November 2021, the Social Democratic party in Switzerland urged the government to buy Novartis AG’s generics and biosimilars unit, Sandoz. 

64 MD002129

Biocon Biologics and Serum Institute Life Sciences partnership

Home/Pharma News | Posted 12/11/2021

On 16 September 2021, a strategic partnership was announced between India-based biologicals specialist Biocon Biologics Limited (BBL), and Indian vaccine manufacturer Serum Institute Life Sciences (SILS), a subsidiary of Serum Institute of India Pvt Ltd.

Contract Tender V13H30

Ustekinumab biosimilars: new international biopharma agreements

Home/Pharma News | Posted 12/11/2021

September and October 2021 saw new international agreements between biopharmaceutical companies regarding ustekinumab biosimilars. These were formed between BioFactura and Rani Therapeutics in the US, and China’s Bio-Thera Solutions and Pharmapark in Russia. 

12 AA010179

Agreement to produce similar biotherapeutic product in Turkey

Home/Pharma News | Posted 05/11/2021

On 22 October 2021, an important agreement was signed between Nobel Pharmaceuticals and the IBG-OzBio partnership for the manufacturing of a similar biotherapeutic product in Turkey. This hopes to be a springboard for further collaborations and medicinal product development in the country. 

Cancer Cell V13I20

Collaborations to commercialize oncology biosimilars

Home/Pharma News | Posted 22/10/2021

New collaborations to commercialize oncology biosimilars have been announced between Sandoz and Bio-Thera Solutions, and between Innovent Biologics and Ascentage Pharma.

IBD 1

Licensing agreements signed for ustekinumab biosimilars

Home/Pharma News | Posted 17/09/2021

Bio-Thera Solutions have signed an exclusive commercialization and licensing agreement with Hikma Pharmaceuticals for the ustekinumab (Stelara) biosimilar BAT2206, similar to an agreement reached between Meiji Seika Pharma, Dong-A ST and Intas Pharmaceuticals.

104 MD001918

Oncogen–BrightGene partnership

Home/Pharma News | Posted 10/09/2021

In June 2021, Malaysian oncology generics company, Oncogen, and China’s BrightGene Bio-Medical Technology announced that they are partnering to develop, manufacture, market and distribute generic drug products for the US market. 

01 AA007239

Menagen–CKD Middle Eastern partnership

Home/Pharma News | Posted 03/09/2021

Omani company, Menagen Pharmaceutical Industries and Korean company, Chong Kun Dang Pharmaceutical Corp (CKD), have formed a strategic partnership to provide biosimilars to countries in the Middle East.

VEGF allaboutvision.com V21D02

Teva signs deal with Bioeq for ranibizumab biosimilar FYB201

Home/Pharma News | Posted 30/07/2021

Israeli generics giant Teva Pharmaceutical Industries (Teva) and Swiss biotechnology company Bioeq AG announced on 28 June 2021 that they had entered into a strategic partnership for the exclusive commercialization of Bioeq’s candidate ranibizumab biosimilar (FYB201) in Europe, Canada, Israel and New Zealand.

Follitropin V13I20

Organon launches as new global women’s health company and appoints leaders in Latin America

Home/Pharma News | Posted 23/07/2021

Organon celebrated its launch as a global women’s health company on 3 June 2021 with employees and women from around the world, as the Organon executive leadership team rings the opening bell at the New York Stock Exchange.

134 AA010709

Prestige-Cytiva partnership and new Korean R & D facility

Home/Pharma News | Posted 09/07/2021

Singapore-based Prestige BioPharma, which specializes in the development of antibody therapeutics, is to build a new research and development (R & D) facility in the Republic of Korea and has entered a strategic partnership with Cytiva.

18794124_l

Theramex to market Prolia biosimilar in Europe and Australia

Home/Pharma News | Posted 25/06/2021

UK-based pharmaceutical company Theramex UK Ltd, which focuses on women’s health, has announced an agreement with India’s Enzene Biosciences Limited for the registration and commercialisation of a Prolia (denosumab) biosimilar in Europe and Australia.

Antitrust V21F04

AbbVie antitrust investigation and Sandoz biosimilar delay

Home/Pharma News | Posted 04/06/2021

In May 2021, following the release of a report, it was announced that AbbVie is likely to be subject to an antitrust investigation due to claims it has delayed market entry of biosimilars of Humira (adalimumab). Alvotech also raised a complaint against AbbVie after being sued over their Humira biosimilar application. In addition, the US Supreme Court denied Sandoz the ability to release its Enbrel (etanercept) biosimilar.

Business Aquisition V13F07

Merck partners with Indian drugmakers to increase access to COVID-19 drug

Home/Pharma News | Posted 21/05/2021

On 27 April 2021, Merck & Co Inc (also known as MSD Pharmaceuticals) announced that it had partnered with five Indian generic drug manufacturers to expand production and access to its experimental COVID-19 drug.